Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

Ozempic and Wegovy maker Novo ... hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...

As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...

Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Semaglutide Market Size, Share & Trends Analysis Report by Product (Ozempic ... limiting generic competition and ensuring continued market exclusivity ...

As global shortages hit Ozempic and Wegovy, rivals like Eli Lilly gain ground, including in India’s growing market for ...

Danish pharmaceutical giant Novo Nordisk is saying goodbye to its chief executive amid growing competition for its ...

"Considering the recent market challenges ... Novo Nordisk also manufactures Ozempic, which is FDA-approved for the treatment of type 2 diabetes and in competition with Lilly's Mounjaro, which ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The recent dismissal of 13 FDA review staff eliminated precisely the kind of government spending that delivered the most bang ...

Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover ...